Core Insights - The FDA has approved ICOTYDE™ (icotrokinra), a targeted oral peptide for the treatment of moderate-to-severe plaque psoriasis, marking a significant advancement in systemic therapy options for patients [1][2][3] Product Overview - ICOTYDE is the first and only IL-23 receptor antagonist available in oral form, designed for patients aged 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy [1][7] - The medication is taken once daily, providing a convenient option for patients [6][7] Clinical Evidence - ICOTYDE demonstrated efficacy in four Phase 3 studies involving 2,500 patients, meeting all primary efficacy endpoints [1][3] - In head-to-head trials, approximately 70% of patients achieved clear or almost clear skin (IGA 0/1), and 55% achieved a PASI 90 response at Week 16 [1][3] - Adverse reaction rates were comparable to placebo, with no new safety signals identified through Week 52 [1][3] Market Need - Over 8 million Americans suffer from psoriasis, with many requiring systemic treatments due to the inadequacy of topical therapies [1][4] - The approval of ICOTYDE aligns with the International Psoriasis Council's guidance for transitioning to systemic therapy after ineffective topical treatments [1][4] Company Commitment - Johnson & Johnson is dedicated to patient access and support through the ICOTYDE withMe program, which offers resources and assistance regardless of insurance type [2][6] - The company aims to redefine treatment expectations for plaque psoriasis through innovative solutions [1][4]

Market Overview - The Dow Jones Industrial Average increased by 46.85 points (0.10%) to reach 46,993.26, influenced by central bank policies and geopolitical risks [1] - The Federal Open Market Committee (FOMC) meeting is a key focus, with expectations that the Federal Reserve will maintain interest rates while monitoring the impact of rising energy costs on inflation [1] - Dow Futures showed positive momentum, rising by 201.00 points (0.42%) to 47,549.00 [1] Company Performances - IBM led the blue-chip gains, increasing by 2.71% to $256.11, driven by strong demand for enterprise-grade AI solutions [2] - Disney saw a 1.75% rise to $100.30, while Amazon increased by 1.48% to $215.20 [2] - Goldman Sachs rose by 1.41% to $807.04, as traders anticipated a stabilizing yield environment [2] - Other notable gainers included Nike, up 0.78% to $55.12, and American Express, which rose by 0.76% to $300.27 [2] Sector Performance - The healthcare and industrial sectors faced declines, with Johnson & Johnson down 2.09% to $238.11 due to litigation concerns [3] - Salesforce dropped by 1.48% to $195.31, and Amgen declined by 1.38% to $361.13 [3] - Boeing fell by 1.34% to $210.82 amid geopolitical instability affecting supply chains and fuel costs [3] - Honeywell and Verizon also experienced declines of 1.32% and 1.01%, respectively, as investors shifted away from defensive positions [3]

Market Performance - U.S. equity markets rebounded on March 17, 2026, with the S&P 500 rising 0.6% to 6,741.72, the Dow Jones increasing by 217.44 points (approximately 0.5%) to 47,163.85, and the Nasdaq Composite gaining 0.7% to close at 22,526.29 [1] - Positive sentiment was driven by optimism that geopolitical tensions in the Persian Gulf would not lead to long-term stagflation, despite elevated crude oil prices around $93.38 per barrel [2] Sector Performance - The financial and technology sectors were the main growth drivers, with Goldman Sachs gaining 2.57%, IBM rising 2.29%, and American Express increasing by 2.01% [3] - In technology, Nvidia's stock rose after reaffirming its forecast of $1 trillion in AI chip revenue by 2027, while Qualcomm jumped 3% following a dividend hike and a $20 billion share buyback announcement [4] Defensive Sector Trends - Defensive sectors faced pressure, with Johnson & Johnson falling 0.96%, and Amgen and Coca-Cola also declining as investors shifted towards growth-oriented assets [5] Travel Sector Developments - Delta Air Lines shares surged 6.6% after raising its revenue forecast for Q1 2026, citing increased demand from business and leisure travelers, which helped offset higher jet fuel costs [6] - This positive outlook led to a sector-wide rally, boosting American Airlines by 3.5%, United Airlines by 3.2%, and Southwest Airlines by 2.2% [6] Upcoming Market Events - Investors are focused on the Federal Reserve's policy decision on March 18, with expectations of interest rates remaining steady at 3.75% [7] - A wave of economic data, including housing starts and industrial production figures, is anticipated later in the week to provide insights into U.S. consumer health amid energy price volatility [8] After-Hours Earnings Highlights - Major companies like Walmart are under scrutiny for retail health, while tech firms such as Arista Networks and cloud-computing companies are expected to release updates that may impact market sentiment [9]

Core Viewpoint - Johnson & Johnson has demonstrated strong performance in the healthcare sector, with a notable increase in share price over the past year and year-to-date [1] Summary by Category Company Performance - Johnson & Johnson's shares have increased by 48% over the past 12 months [1] - The company has seen a 16% rise in share price year-to-date [1]

Group 1 - Johnson & Johnson (JNJ) has submitted a Type II variation application to the European Medicines Agency for TECVAYLI (teclistamab) as a treatment for relapsed and refractory multiple myeloma [1][3] - The company aims to improve long-term outcomes for multiple myeloma patients with the approval of TECVAYLI, supported by data from the Phase 3 MajesTEC-9 trial, which indicated a clinically manageable safety profile for teclistamab monotherapy [3] - The submission follows the European Commission's approval of an indication extension for AKEEGA in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer, providing a new precision-based treatment option [4][5] Group 2 - Johnson & Johnson is a diversified global healthcare company operating in two primary segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices) [5]

Core Insights - Johnson & Johnson (JNJ) reported positive results from an early-stage study of its investigational drug delivery system, Erda-iDRS, for treating intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) [1][3] Group 1: Study Results - The phase I study demonstrated that Erda-iDRS met its primary safety endpoint and showed encouraging clinical activity, with an 89% complete response (CR) rate in the intermediate-risk cohort and a median response duration of 18 months [6][7] - In the high-risk cohort, patients exhibited a median recurrence-free survival of 20 months, with an 83% recurrence-free survival rate at 12 months [8] - The treatment was well-tolerated, with no dose-limiting toxicities and most adverse events being mild to moderate [9] Group 2: Study Population and Design - The study included patients with recurrent intermediate-risk NMIBC and high-risk disease who had previously experienced Bacillus Calmette-Guérin (BCG) therapy, specifically targeting those with FGFR alterations [4][6] - A total of 62 patients in the intermediate-risk group and 26 in the high-risk group were treated as of November 3, 2025 [4] Group 3: Future Development - Positive findings from the early-stage study support ongoing phase II and III studies under J&J's MoonRISe program, which aims to evaluate Erda-iDRS across various NMIBC risk settings [10][12] - The program includes multiple studies, such as MoonRISe-1 for adjuvant treatment post-tumor resection and MoonRISe-3 for high-risk patients previously treated with BCG [12]

Core Insights - Monte Rosa Therapeutics (GLUE) has entered into a supply agreement with Johnson & Johnson (JNJ) to evaluate its MRT-2359 in combination with apalutamide for the treatment of metastatic castration-resistant prostate cancer [2] Company Developments - The agreement with Johnson & Johnson marks a significant advancement for Monte Rosa Therapeutics as it seeks to enhance its drug development pipeline [2] - MRT-2359 is being evaluated in a clinical setting, indicating progress in the company's research and development efforts [2] Industry Context - The collaboration highlights the ongoing interest and investment in innovative treatments for prostate cancer, particularly in the area of metastatic castration-resistant cases [2] - The partnership with a major player like Johnson & Johnson may provide Monte Rosa Therapeutics with additional resources and credibility in the competitive oncology market [2]

Group 1: Investment Potential - Johnson & Johnson (NYSE: JNJ) is highlighted as a highly profitable blue chip stock, with Citi raising its price target from $250 to $274 while maintaining a Buy rating [1] - Citi's research note indicates that despite recent market volatility, the fundamentals of the medical technology sector remain "healthy" [1] - Citi's top picks in the sector include iRhythm and Medtronic, suggesting a competitive landscape [1] Group 2: Product Development and Regulatory Approvals - Johnson & Johnson announced the submission of a Type II variation application to the European Medicines Agency (EMA) for TECVAYLI® to treat adult patients with relapsed/refractory multiple myeloma [2] - The submission is supported by data from the Phase 3 MajesTEC-9 trial, which evaluates teclistamab's safety and efficacy against standard care in 614 patients [3] Group 3: Company Overview - Johnson & Johnson operates through two segments: Innovative Medicine and MedTech, focusing on various therapeutic areas including oncology, infectious diseases, and cardiovascular diseases [4] - The MedTech segment encompasses a wide range of medical devices used in cardiovascular intervention, orthopedics, and surgery [4]

Core Viewpoint - The article discusses the 12 most profitable blue-chip stocks to invest in currently, emphasizing the importance of diversification and identifying opportunities amidst market volatility [1][2][3]. Market Trends and Investment Strategy - Stephen Parker from JPMorgan Private Bank highlights that geopolitical events, such as the Iran war, can cause short-term market disruptions, particularly in energy markets, but typically do not have long-lasting effects [1][2]. - He advises clients to maintain a diversified and disciplined investment approach, seek opportunities during volatility, and start building a shopping list for potential investments [2][3]. Stock Selection Methodology - The selection of the 12 blue-chip stocks was based on stock screeners and holdings of blue-chip ETFs, focusing on those with the highest trailing twelve months (TTM) net income and net income margins [5]. - The list prioritizes stocks with the highest number of hedge fund holders as of Q3 2025, utilizing data from Insider Monkey's database [5][6]. Company Highlights - **AstraZeneca PLC (NASDAQ:AZN)**: - Price target raised to 16,000 GBp from 15,500 GBp by Guggenheim, maintaining a Buy rating after positive fiscal 2025 results [8]. - The FDA has accepted a supplemental Biologics License Application for Enhertu, with a Priority Review status for treating HER2-positive breast cancer [9][10]. - AstraZeneca focuses on developing and commercializing prescription medicines, including novel immuno-oncology treatments [11]. - **Johnson & Johnson (NYSE:JNJ)**: - Citi increased the price target to $274 from $250 while maintaining a Buy rating, citing healthy sector fundamentals despite recent volatility [12]. - The company submitted a Type II variation application to the EMA for TECVAYLI® to treat relapsed/refractory multiple myeloma [13][14]. - Johnson & Johnson operates in healthcare, with segments in Innovative Medicine and MedTech, covering various therapeutic areas and medical devices [15].

Core Viewpoint - The Court has granted preliminary approval for a $65 million settlement in an antitrust class action against Actelion Pharmaceuticals, now part of Johnson & Johnson, for allegedly preventing generic drug manufacturers from developing a cheaper version of its drug Tracleer [1] Group 1: Lawsuit Details - The lawsuit was initiated by the Government Employees Health Association (GEHA), which claimed that Actelion obstructed generic manufacturers from obtaining necessary samples of Tracleer, thereby hindering the market entry of generic alternatives [2] - GEHA alleged that Actelion not only refused to sell samples but also contractually prevented competitors from acquiring samples from pharmacies, effectively blocking all avenues for generic manufacturers [2] - The alleged actions resulted in no generic product being available for nearly four years after the Tracleer patent expired, leading to over $100 million in overpayments by GEHA and other Third-Party Payors for the drug [2] Group 2: Settlement and Impact - The settlement amount of $65 million represents nearly 50% of the conservative single damages estimate, providing significant relief to the class of entities that purchased Tracleer [3] - If finalized, the settlement will resolve over seven years of litigation and deliver compensation to those affected by the alleged antitrust practices [3] Group 3: Drug Information - Tracleer, the brand name for bosentan, is used to treat pulmonary artery hypertension (PAH), a chronic and potentially fatal condition affecting 10,000 to 20,000 people in the U.S., primarily women [4] - At the time of the alleged antitrust scheme, Actelion charged $75,000 per patient annually for Tracleer [4] Group 4: Legal Proceedings - The lawsuit was originally filed in 2018 but was dismissed in 2019 due to statute of limitations issues; however, the Fourth Circuit revived the case in 2021, allowing it to proceed [5] - The district court granted class certification for GEHA in September 2024, denying Actelion's motion for summary judgment, which set the stage for the trial [5]